C4 Therapeutics, Inc.
cemsidomide
Multiple Myeloma
Countdown
543days
Phase 3 readout · ~ Jan 1, 2028 estimated
What's at stake
Phase 3 trial results for cemsidomide in Multiple Myeloma are due ~ Jan 1, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“By early 2028: Initiate the Phase 3 trial in combination with a BCMAxCD3 Bispecific”